Abstract
Ocular toxoplasmosis is the most common cause of infectious posterior uveitis. Available literature is still conflicting regarding the incidence of recurrence during pregnancy as various calculations were employed in the different published studies. Although earlier reports have suggested a difference in presentation and an increase in severity during pregnancy, newer studies appear to show otherwise. Further diagnostic testing, including serologic and intraocular fluid sampling, may be indicated to increase the diagnostic accuracy in this special population of patients. The management of ocular toxoplasmosis during pregnancy is challenging as the foetus is additionally considered in the choice of treatment. Traditionally preferred anti-toxoplasmosis regimens containing antifolate drugs, such as pyrimethamine and trimethoprim-sulfamethoxazole, cannot be used routinely in pregnant patients, especially during the first trimester. This review includes literature on alternative treatments for ocular toxoplasmosis during pregnancy, including spiramycin and intravitreal treatment options.
摘要
眼弓形虫病是感染性后葡萄膜炎最常见的病因。关于妊娠期复发的发生率, 在发表的研究中仍存在矛盾, 因为不同文献采用了不同的计算方法。虽然早期文献认为妊娠期的表现有所不同, 严重程度也会增加, 但最新研究表明情况并非如此。进一步的诊断检测, 包括血清学和眼内液采样, 可提高对这一特殊患者群体的诊断准确率。妊娠期眼弓形虫病的治疗具有挑战性, 因为在选择治疗方法时还要考虑到胎儿。传统上首选的抗弓形虫治疗方案含有抗叶酸药物, 如乙胺嘧啶和三甲氧苄氨嘧啶-磺胺甲噁唑, 但不能常规用于孕妇, 尤其是妊娠头三个月。本综述收录了有关妊娠期眼弓形虫病替代治疗的文献, 包括螺旋霉素和玻璃体内治疗方案。
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Grotting LA, Papaliodis GN. A review of the course and treatment of non-infectious uveitis during pregnancy. Semin Ophthalmol. 2017;32:75–81.
Rabiah PK, Vitale AT. Noninfectious uveitis and pregnancy. Am J Ophthalmol. 2003;136:91–8.
Chiam NPY, Hall AJH, Stawell RJ, Busija L, Lim LLP. The course of uveitis in pregnancy and postpartum. Br J Ophthalmol. 2013;97:1284–8.
Kump LI, Cervantes-Castañeda RA, Androudi SN, Foster CS, Christen WG. Patterns of exacerbations of chronic non-infectious uveitis in pregnancy and puerperium. Ocul Immunol Inflamm. 2006;14:99–104.
Holland GN. Ocular toxoplasmosis: a global reassessment. Part II: disease manifestations and management. Am J Ophthalmol. 2004;137:1–17.
Garweg JG, Scherrer J, Wallon M, Kodjikian L, Peyron F. Reactivation of ocular toxoplasmosis during pregnancy. BJOG. 2005;112:241–2.
Braakenburg AMD, Rothova A. Clinical features of ocular toxoplasmosis during pregnancy. Retina. 2009;29:627–30.
Ramchandani M, Weaver JB, Joynson DHM, Murray PI. Acquired ocular toxoplasmosis in pregnancy. Br J Ophthalmol. 2002;86:938–9.
Kump LI, Androudi SN, Foster CS, Facs MD. Ocular toxoplasmosis in pregnancy. Clin Exp Ophthalmol. 2005;33:455–60.
Braakenburg AMD, Crespi CM, Holland GN, Wu S, Yu F, Rothova A. Recurrence rates of ocular toxoplasmosis during pregnancy. Am J Ophthalmol. 2014;157:767–73.
Reich M, Ruppenstein M, Becker MD, Mackensen F. Risk of recurrence of preexisting ocular toxoplasmosis during pregnancy. Ocul Immunol Inflamm. 2015;23:240–5.
Brydak-Godowska J, Borkowski PK, Rabczenko D, Moneta-Wielgoś J, Kęcik D. Do pregnancy, postpartum period and lactation predispose to recurrent toxoplasmic retinochoroiditis? Med Sci Monit. 2015;21:582–4.
Martinez CE, Zhang D, Conway MD, Peyman GA. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. Int Ophthalmol. 1999;22:85–8.
Kalogeropoulos D, Sakkas H, Mohammed B, Vartholomatos G, Malamos K, Sreekantam S, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42:295–321.
Paquet C, Yudin MH, Yudin MH, Allen VM, Bouchard C, Boucher M, et al. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. 2013;35:78–9.
Bigna JJ, Tochie JN, Tounouga DN, Bekolo AO, Ymele NS, Youda EL, et al. Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: a systematic review, modelling and meta-analysis. Sci Rep. 2020;10:12102.
Murata, Previato FHA, Frederico M, Barbosa FB, Nakashima AP, Faria F, et al. Evaluation of serological and molecular tests used for the identification of toxoplasma gondii infection in patients treated in an ophthalmology clinic of a public health service in São Paulo State, Brazil. Front Cell Infect Microbiol. 2020;9:472.
De Groot-Mijnes JDF, Rothova A, Van Loon AM, Schuller M, Ten Dam-Van Loon NH, De Boer JH, et al. Polymerase chain reaction and Goldmann-Witmer coefficient analysis are complimentary for the diagnosis of infectious uveitis. Am J Ophthalmol. 2006;141:313–8.
Rothova A, de Boer JH, ten Dam-van Loon NH, Postma G, de Visser L, Zuurveen SJ, et al. Usefulness of aqueous humor analysis for the diagnosis of posterior uveitis. Ophthalmology. 2008;115:306–11.
Bourdin C, Busse A, Kouamou E, Touafek F, Bodaghi B, Le Hoang P, et al. PCR-based detection of Toxoplasma gondii DNA in blood and ocular samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol. 2014;52:3987–91.
Fekkar A, Bodaghi B, Touafek F, Le Hoang P, Mazier D, Paris L. Comparison of immunoblotting, calculation of the goldmann-witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol. 2008;46:1965–7.
Holland GN, Lewis KG. Perspective: an update on current practices in the management of ocular toxoplasmosis. Am J Ophthalmol. 2002;134:102–14.
Yogeswaran K, Furtado JM, Bodaghi B, Matthews JM, Smith JR. Current practice in the management of ocular toxoplasmosis. Br J Ophthalmol. 2023;107:973–9.
Pernia S, DeMaagd G. The new pregnancy and lactation labeling rule. P T 2016;41:713–5.
Davis SM, Anderson BL, Schulkin J, Jones K, Eng JVanden, Jones JL. Survey of obstetrician-gynecologists in the United States about toxoplasmosis: 2012 update. Arch Gynecol Obstet. 2015;291:545–55.
Mandelbrot L, Kieffer F, Wallon M, Winer N, Massardier J, Picone O, et al. Toxoplasmosis in pregnancy: practical management. Gynecol Obstet Fertil Senol. 2021;49:782–91.
Gratzl R, Sodeck G, Platzer P, Jäger W, Graf J, Pollak A, et al. Treatment of toxoplasmosis in pregnancy: concentrations of spiramycin and neospiramycin in maternal serum and amniotic fluid. Eur J Clin Microbiol Infect Dis. 2002;21:12–6.
Brydak-Godowska J, Moneta-Wielgoś J, Kęcik D, Borkowski PK. Management of toxoplasmic retinochoroiditis during pregnancy, postpartum period and lactation: clinical observations. Med Sci Monit. 2015;21:598–603.
Zuluaga LM, Hernández JC, Castaño CF, Donado JH. Efecto del tratamiento prenatal con espiramicina en la frecuencia de retinocoroiditis por toxoplasmosis congénita en una cohorte colombiana. Biomedica. 2017;37:86–91.
Schoondermark-van de Ven EM, Melchers WJ, Galama J, Meuwissen JH, Eskes TK. Prenatal diagnosis and treatment of congenital Toxoplasma gondii infections: an experimental study in rhesus monkeys. Eur J Obstet Gynecol Reprod Biol. 1997;74:183–8.
Li P, Qin X, Tao F, Huang K. Maternal exposure to sulfonamides and adverse pregnancy outcomes: a systematic review and meta-analysis. PLoS One. 2020;15:e0242523.
Mandelbrot L, Kieffer F, Sitta R, Laurichesse-Delmas H, Winer N, Mesnard L, et al. Prenatal therapy with pyrimethamine + sulfadiazine vs spiramycin to reduce placental transmission of toxoplasmosis: a multicenter, randomized trial. Am J Obstet Gynecol. 2018;219:386.e1–e9.
Mack D, McLeod R. New micromethod to study the effect of antimicrobial agents on toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother. 1984;26:26–30.
Ardabili S, Kohl J, Gül G, Hodel M. What obstetricians should be aware of: serious side effects of antibiotic toxoplasmosis treatment in pregnancy. BMJ Case Rep. 2021;14:e240809.
Valentini P, Buonsenso D, Barone G, Serranti D, Calzedda R, Ceccarelli M, et al. Spiramycin/cotrimoxazole versus pyrimethamine/sulfonamide and spiramycin alone for the treatment of toxoplasmosis in pregnancy. J Perinatol. 2015;35:90–4.
Silveira C, Muccioli C, Nussenblatt R, Belfort R. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis: 10 years of follow-up. Ocul Immunol Inflamm. 2015;23:246–7.
Fernandes Felix JP, Cavalcanti Lira RP, Cosimo AB, Cardeal da Costa RL, Nascimento MA, Leite Arieta CE. Trimethoprim-sulfamethoxazole versus placebo in reducing the risk of toxoplasmic retinochoroiditis recurrences: a three-year follow-up. Am J Ophthalmol. 2016;170:176–82.
Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Med Sci Monit. 2012;18:CR296–302.
Lashay A, Mirshahi A, Parandin N, Riazi Esfahani H, Mazloumi M, Reza Lashay M, et al. A prospective randomized trial of azithromycin versus trimethoprim/sulfamethoxazole in treatment of toxoplasmic retinochoroiditis. J Curr Ophthalmol. 2017;29:120–5.
Lam S, Tessler HH. Quadruple therapy for ocular toxoplasmosis. Can J Ophthalmol. 1993;28:58–61.
Yates WB, Chiong F, Zagora S, Post JJ, Wakefield D, McCluskey P. Ocular toxoplasmosis in a tertiary referral center in Sydney Australia-clinical features, treatment, and prognosis. Asia-Pac J Ophthalmol. 2019;8:280–4.
Winterhalter S, Severing K, Stammen J, Maier AK, Godehardt E, Joussen AM. Does atovaquone prolong the disease-free interval of toxoplasmic retinochoroiditis? Graefe’s Arch Clin Exp Ophthalmol. 2010;248:1187–92.
Pearson PA, Piracha AR, Sen HA, Jaffe GJ. Atovaquone for the treatment of toxoplasma retinochoroiditis in immunocompetent patients. Ophthalmology. 1999;106:148–53.
Reis A, Valmaggia C, Tandogan T, Rippel K, Girmann O. Atovaquone: a valuable therapeutic option in toxoplasma retinochoroiditis. J Clin Exp Ophthalmol. 2015;06:1–4.
Jasper S, Vedula SS, John SS, Horo S, Sepah YJ, Nguyen QD. Corticosteroids as adjuvant therapy for ocular toxoplasmosis. Cochrane Database Syst Rev. 2017;2017:1–16.
Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS, et al. Interventions for toxoplasma retinochoroiditis: a report by the American Academy of Ophthalmology. Ophthalmology. 2013;120:371–8.
Bosch-Driessen LEH, Berendschot TTJM, Ongkosuwito JV, Rothova A. Ocular toxoplasmosis clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869–78.
Beitins IZ, Bayard F, Ances IG, Kowarski A, Migeon CJ. The transplacental passage of prednisone and prednisolone in pregnancy near term. J Pediatr. 1972;81:936–45.
van Runnard Heimel PJ, Schoben AFAM, Huisjes AJM, Franx A, Bruinse HW. The transplacental passage of prednisolone in pregnancies complicated by early-onset HELLP syndrome. Placenta. 2005;26:842–5.
Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmun Rev. 2016;15:955–63.
Murphy KE, Willan AR, Hannah ME, Ohlsson A, Kelly EN, Matthews SG, et al. Effect of antenatal corticosteroids on fetal growth and gestational age at birth. Obstet Gynecol. 2012;119:917–23.
Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A review of systemic corticosteroid use in pregnancy and the risk of select pregnancy and birth outcomes. Rheum Dis Clin North Am. 2017;43:489–502.
østensen M, Förger F. Management of RA medications in pregnant patients. Nat Rev Rheumatol. 2009;5:382–90.
Fredrickson JS, Holmes J, Cathcart JN, Lynch AM, Kolfenbach JR, Palestine AG. Specialty management differences of syphilis and toxoplasmosis surrounding pregnancy: a prospective cross-sectional study. J Ophthalmic Inflamm Infect. 2018;8:10.
Soheilian M, Ramezani A, Azimzadeh A, Sadoughi MM, Dehghan MH, Shahghadami R, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology. 2011;118:134–41.
Baharivand N, Mahdavifard A, Fouladi RF. Intravitreal clindamycin plus dexamethasone versus classic oral therapy in toxoplasmic retinochoroiditis: a prospective randomized clinical trial. Int Ophthalmol. 2013;33:39–46.
Bor’i A, Mahrous A, Al-Aswad MA, Al-Nashar HY, Nada WM, Wagih M, et al. Intravitreal clindamycin and dexamethasone combined with systemic oral antitoxoplasma therapy versus intravitreal therapy alone in the management of toxoplasma retinochoroiditis: a retrospective study. J Ophthalmol. 2018;2018:4160837.
Zamora YF, Arantes T, Reis FA, Garcia CR, Ferreira Saraceno JJ, et al. Local treatment of toxoplasmic retinochoroiditis with intravitreal clindamycin and dexamethasone. Arq Bras Oftalmol. 2015;78:216–9.
Lasave AF, Daz-Llopis M, Muccioli C, Belfort R, Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology. 2010;117:1831–8.
Choudhury H, Jindal A, Pathengay A, Bawdekar A, Albini T, Flynn HW. The role of intravitreal trimethoprim/sulfamethoxazole in the treatment of toxoplasma retinochoroiditis. Ophthalmic Surg Lasers Imaging Retin. 2015;46:137–40.
Tripathy K. Comment on: ‘Intravitreal injection of sulfamethoxazole and trimethoprim associated with dexamethasone as an alternative therapy for ocular toxoplasmosis.’ Ocul Immunol Inflamm. 2018;26:1045–6.
Souza CE, Nascimento H, Lima A, Muccioli C, Belfort R. Intravitreal injection of sulfamethoxazole and trimethoprim associated with dexamethasone as an alternative therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2018;26:1041–4.
SOBRIN L, KUMP LI, FOSTER CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina. 2007;27:952–7.
Hosseini SM, Abrishami M, Mehdi Zadeh M. Intravitreal clindamycin in the treatment of unresponsive zone one toxoplasmic chorioretinitis: a case report. Iran Red Crescent Med J. 2014;16:1–3.
Verma L, Thulasidas M, Gupta A. Intravitreal clindamycin as first-line therapy for toxoplasmic retinochoroiditis: a case series. Clin Ophthalmol. 2020;14:4279–85.
Tabuenca del Barrio L, Heras Mulero H, Mozo Cuadrado M, Fanlo Mateo P, Compains Silva E. Clindamicina intravítrea como alternativa terapéutica en la toxoplasmosis ocular severa. Arch Soc Esp Oftalmol. 2019;94:602–4.
Feliciano-Alfonso JE, Muñoz-Ortiz J, Marín-Noriega MA, Vargas-Villanueva A, Triviño-Blanco L, Carvajal-Saiz N, et al. Safety and efficacy of different antibiotic regimens in patients with ocular toxoplasmosis: systematic review and meta-analysis. Syst Rev. 2021;10:206.
Fernandes-Cunha GM, Fialho SL, da Silva GR, Silva-Cunha A, Zhao M, Behar-Cohen F. Ocular safety of intravitreal clindamycin hydrochloride released by PLGA implants. Pharm Res. 2017;34:1083–92.
Jorge R, Coelho IN, Silva-Cunha A, Fernandes Cunha GM, Scott IU, Fialho SL, et al. Use of a slow-release intravitreal clindamycin implant for the management of ocular toxoplasmosis. Am J Ophthalmol Case Rep. 2021;22:101093.
Ahmed A, Sudharshan S, Gopal S, Majumder PD, Biswas J. Toxoplasma retinitis following intravitreal injection of triamcinolone acetonide: a case report and review of literature. Indian J Ophthalmol. 2018;66:1205–8.
Rush R, Sheth S. Fulminant toxoplasmic retinochoroiditis following intravitreal triamcinolone administration. Indian J Ophthalmol. 2012;60:141–3.
Nóbrega MJ, Rosa EL. Toxoplasmosis retinochoroiditis after photodynamic therapy and intravitreal triamcinolone for a supposed choroidal neovascularization: a case report. Arq Bras Oftalmol. 2007;70:157–60.
Olson DJ, Parhiz AT, Wirthlin RS. Reactivation of latent toxoplasmosis following dexamethasone implant injection. Ophthalmic Surg Lasers Imaging Retin. 2016;47:1050–2.
Backhouse O, Bhan KJ, Bishop F. Intravitreal triamcinolone acetonide as an adjunct in the treatment of severe ocular toxoplasmosis. Eye. 2008;22:1201–2.
Gaballa SA, Kompella UB, Elgarhy O, Alqahtani AM, Pierscionek B, Alany RG, et al. Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv Transl Res. 2021;11:866–93.
Kuppermann BD, Cabral L, Md Z, Kenney MCSTEROID. Differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2014;112:116–41.
O’Connor GR, Frenkel JK. Dangers of steroid treatment in toxoplasmosis. Arch Ophthalmol. 1976;94:213.
Nijhawan R, Bansal R, Gupta N, Beke N, Kulkarni P, Gupta A. Intraocular cysts of Toxoplasma gondii in patients with necrotizing retinitis following periocular/intraocular triamcinolone injection. Ocul Immunol Inflamm. 2013;21:396–9.
Author information
Authors and Affiliations
Contributions
JCMA had the lead role in conceptualising the review, collecting and analysing data for the review and writing the initial and final manuscript. CPA, FDL and AJB collected and analysed data and had major contributions to writing the manuscript and approving its final version. BVQM and CAA contributed critical appraisal of initial manuscript and approval of final manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Artiaga, J.C.M., Azarcon, C.P., Levina, F.D. et al. Considerations in the management of ocular toxoplasmosis in pregnancy: a review of literature. Eye (2024). https://doi.org/10.1038/s41433-023-02916-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-023-02916-y